Kiora Pharmaceuticals FY2025 loss widens to $10.8M, two Phase 2 trials underway
Clinical-stage biotech posts loss after 2024's Théa payment; cash runway extends into late 2027
Kiora Pharmaceuticals reported a fiscal year 2025 net loss of $10.8 million, swinging from net income of $3.6 million in the prior year, as the clinical-stage biotechnology company advances two mid-stage clinical trials for retinal diseases. The shares were little changed at approximately $2.06 following the announcement.
The year-over-year comparison was significantly distorted by a $16 million upfront payment received from Théa Open Innovation in 2024 as part of a strategic partnership. That payment, which boosted 2024 results, was not repeated in the current fiscal period, according to the company's fourth quarter and full year 2025 results.
Despite the headline loss, the company's cash position appears robust for a development-stage company. Kiora ended 2025 with $17.1 million in cash, cash equivalents, and short-term investments, plus $3.5 million in receivables. Management projects this capital will fund operations into late 2027, extending beyond anticipated topline data readouts from its ongoing clinical programs.
"2025 was defined by the transition from trial preparation to trial execution for our two lead programs, KLARITY and ABACUS-2, both of which are now underway, actively recruiting, and dosing patients," said Brian M. Strem, Ph.D., president and chief executive officer. "We anticipate clinical data in the first half of 2027."
Research and development expenses reached $10.8 million before recognizing $7.1 million in reimbursable expenses from Théa, up from $7.8 million in 2024. The increase was driven primarily by clinical trial activities for KIO-301 and KIO-104. General and administrative expenses rose modestly to $5.8 million from $5.5 million.
The company's pipeline centers on two Phase 2 programs. The ABACUS-2 trial is evaluating KIO-301, a molecular photoswitch designed to restore vision in patients with advanced inherited retinal diseases such as retinitis pigmentosa. The multi-center, double-masked, randomized study will enroll 36 patients with ultra-low vision or no light perception. Multiple trial sites have been activated and the first cohort of patients has been dosed, with an initial data readout expected in the third quarter of 2027.
The KLARITY Phase 2 trial is investigating KIO-104, a potent, locally delivered small molecule for inflammatory retinal diseases including retinal macular edema secondary to diabetic retinopathy. The multi-center, open-label study plans to enroll up to 28 patients to evaluate safety, tolerability, reduction of macular edema, and improvement in visual acuity. KIO-104 has received U.S. patent protection extending market exclusivity into 2043.
Kiora has secured two strategic partnerships to support development. In January 2024, the company entered into an agreement with Théa Open Innovation granting the French pharmaceutical company exclusive worldwide development and commercialization rights for KIO-301 in all global territories except Asia. The partnership carries a total potential value of up to $301 million, including the upfront payment and up to $285 million in development, regulatory, and commercial milestones, plus tiered royalties on net sales.
In June 2025, Kiora granted Senju Pharmaceutical an exclusive option for the development and commercialization of KIO-301 in key Asian markets including Japan and China. The option agreement has a potential value of up to $110 million plus royalties. Kiora received an immediate $1.25 million option fee, with additional mid-single-digit million upfront payments and development milestones due if Senju exercises the option. The combined potential value of both partnerships exceeds $400 million.
Melissa Tosca, chief financial officer, emphasized the company's financial discipline, stating that the projected cash runway "is expected to extend beyond the anticipated initial data readouts from both ongoing clinical trials."
Analysts maintain a bullish outlook on the stock, with an average price target of $12.00 representing substantial upside from current levels around $2.06. The company's market capitalization stands at approximately $7.5 million. Both KIO-301 and KIO-104 have received orphan drug designations in the U.S. and European Union, providing potential market exclusivity and regulatory incentives.
Kiora's focus on retinal diseases addresses significant unmet medical needs. Retinitis pigmentosa affects approximately 1 in 4,000 people globally, with no approved treatments to restore vision in advanced stages. The company's approach of targeting surviving retinal ganglion cells rather than photoreceptors is mutation-agnostic, potentially benefiting patients regardless of the specific genetic cause of their disease.